Category: Consumer goods
Quick infos Trade prices Volume: Market Cap: 5.14B Prev closed: Open: High: Low: 52 week low: 52 week high: Dividends: Next ER: May 11, 2022 After Market Closes
Earnings History Date EPS / Forecast Revenue / Forecast May 24, 2022 March 2, 2022 -1.86 / -2.34.9M / 2.7MBeat! November 10, 2021 -1.47 / -2.311.11M / 1.14MAugust 25, 2021 -2.5 / -2.231.02M / 746.84KMay 27, 2021 -1.17 / -1.82746K / 1.64MBeat! view more
Historical Data Date Price Open High Low Vol Change ER May 19, 2022 91.13 86.16 91.29
85.00
537.07K 5.97% May 18, 2022 86.00 87.42 89.44
85.34
425.73K -3.34% May 17, 2022 88.97 86.06 90.93
85.03
447.68K 5% May 16, 2022 84.73 83.12 85.45
82.62
661.63K 1.94% May 13, 2022 83.12 81.21 85.68
79.36
1.17M 3.89% May 12, 2022 80.01 65.00 81.18
61.58
3.36M 2.47% May 11, 2022 78.08 81.79 84.89
75.75
1.00M -5.52% May 10, 2022 82.64 82.44 87.35
79.43
840.50K 4.74% May 9, 2022 78.90 81.68 83.08
75.70
820.30K -5.03% May 6, 2022 83.08 90.06 91.57
82.20
895.70K -7.91% view more
News
Ascendis Pharma A/S Submits Investigational New Drug Application to Initiate TransCon IL-2 / Clinical Program finance.yahoo.com Oct 20, 2021 4:59 pm
Ascendis Pharma: Q2 Earnings Insights finance.yahoo.com Oct 20, 2021 4:24 pm Ascendis Stock Surges To 6-Month High; FDA Approval Lands It In A Major Market investors.com Oct 20, 2021 4:15 pm
Ascendis Pharma A/S Reports Third Quarter 2020 Financial Results finance.yahoo.com Oct 20, 2021 4:01 pm
Ascendis Pharma A/S Announces U.S. Food and Drug Administration Approval of SKYTROFA® (lonapegsomatropin-tcgd), the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency finance.yahoo.com Oct 20, 2021 3:24 pm
Should You Consider Investing in Ascendis Pharma (ASND)? finance.yahoo.com Oct 20, 2021 1:10 pm
Mid-Day Market Update: Dow Tumbles Over 100 Points; Ascendis Pharma Shares Spike Higher finance.yahoo.com Oct 20, 2021 12:13 pm
Catalyst (CPRX) to Report Q3 Earnings: What's in the Cards? finance.yahoo.com Oct 20, 2021 10:09 am
Implied Volatility Surging for Ascendis Pharma (ASND) Stock Options finance.yahoo.com Oct 20, 2021 8:47 am
Is Ascendis Pharma A/S (ASND) Going to Burn These Hedge Funds? finance.yahoo.com Oct 20, 2021 8:30 am Ascendis Stock Jumps as FDA Clears Growth-Hormone Treatment thestreet.com Oct 20, 2021 7:28 am
Here is What Hedge Funds Think About Ascendis Pharma A/S (ASND) finance.yahoo.com Oct 18, 2021 9:49 am
Pfizer's Growth Hormone Candidate FDA Review Pushed By 3 Months finance.yahoo.com Sep 27, 2021 9:23 am
Medicines Golden Age Is Dawning. 10 Ways to Invest barrons.com Sep 24, 2021 7:51 pm
Ascendis (ASND) Seeks FDA Nod for New Immunotherapy Study finance.yahoo.com Sep 8, 2021 10:57 am
These 2 Stocks Soared Double Digits After Hours fool.com Aug 25, 2021 6:20 pm Ascendis Pharma Q2 2021 Earnings Preview seekingalpha.com Aug 25, 2021 5:35 am Lumos Pharma adds Mark Bachhas to Clinical Scientific Advisory Board seekingalpha.com Jul 27, 2021 4:39 am Ascendis hits target enrollment in late-stage hypoparathyroidism trial seekingalpha.com Jul 6, 2021 8:11 pm
Ascendis Pharma A/S Announces Seven Presentations at ENDO 2021, Demonstrating Commitment to People with Rare Endocrine Diseases finance.yahoo.com Oct 20, 2021 7:05 am Talk about Ascendis Pharma below in comments section below. Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above. This profile is based on publicly available information and is intended to be informative in nature. Most of the datas are collected by our Data Entry and we aim to be as accurate as humanly possible.
Share it with fellow traders:
or join discussions in FB below
(
FB comments )
investors.ascendispharma.com If you are looking for News & events, Press Release, they are available on their Investors Relations site.
If you want to help pay for server cost or for improving this tool. You can send it via Paypal . More features coming soon :)
Buy on Amazon Graham's philosophy of "value investing" has made The Intelligent Investor the stock market bible ever since its original publication in 1949.
The best book on investing ever written. -- Warren Buffet